ARRY hit $2.90 this morning. What are your thoughts? $153 million market cap with $129 million in cash as of the end of 2nd quarter. Is the debt overhang the problem? (It's not due until 2014, right?) Nine drugs in clinical trials with partnerships with NVS, AZN, DNA and Amgen. Are the drugs simply too early-stage for the Street to be interested?